Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2013

View Archived Issues

Identification and suppression of the neuronal circuitry underlying compulsive behavior

Studies characterize activity of Alzheimer's disease candidate RO-4602522

Effects of AZD-5213 on sleep evaluated in patients with MCI and Alzheimer's disease

GlaxoSmithKline profiles pipeline progress of second quarter 2013

Memory improvements seen with insulin detemir in Alzheimer's disease, mild cognitive impairment

Hemophilia candidate concizumab evaluated in phase I trial

Sanofi researchers report antibodies targeting IL-13

New GPR119 receptor agonists patented by Hyundai Pharmaceutical

The Terasaki Family Foundation prepares novel IVIg mimetics

FDA grants market authorization for Cepheid's tuberculosis test

Vertex provides update on ongoing VX-135 trials in hepatitis C

Yakult Honsha begins phase I/II study of resminostat in NSCLC

EMA committee recommends Defitelio approval under exceptional circumstances

EMA's CHMP recommends approval of VEGF Trap-Eye/Eylea for new indication

PolyTherics merges with Antitope

Phosphagenics reaches milestone in development program for TPM/oxycodone patch

Genesis Biopharma and Lion Biotechnologies complete merger

EMA committee recommends approval of Revolade expanded indication

EMA issues negative opinion on delamanid for tuberculosis

Captisol-enabled topiramate injection receives FDA orphan drug status

Adimab licenses antibody discovery platform to Biogen Idec and GSK

Novartis' dual bronchodilator QVA-149 recommended for approval in COPD by CHMP

Gilead receives positive opinion from EMA for cobicistat

EMA committee recommends approval of three Takeda type 2 diabetes therapies

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...